SignalPath, a company that specializes in making software for clinical drug trials, did not indicate its plans for the raised money. The company has completed its offering amount, according to the filing.
It earlier raised $5 million in January 2017 and $2.9 million in February 2016.
Bradford Hirsch, a medical doctor who co-founded SignalPath and serves as the company’s CEO, was listed as the principal contact for the company.
Hirsch became CEO in 2017 after founding the company in 2014. He continues to practice part time as a medical oncologist and is an active principal investigator.
Prior to coming to SignalPath, he served as senior medical director at Flatiron Health, a Google-backed startup working to accelerate treatment and research in oncology, and was on the faculty at Duke University, where he led a clinical informatics research team.
SignalPath works with drug makers to organize various parts of clinical trials, such as tracking participants and data.
Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but must file what’s known as a Form D electronically with the SEC after they first sell their securities.
This story is from the North Carolina Business News Wire, a service of the UNC-Chapel Hill School of Media and Journalism
